Evidence map›Paper›PMID 39722553›Full record

Observational studyJournal of medical virology2024

Seronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity.

Gabriele Anichini, Chiara Terrosi, Giulia Alessandri, Giovanni B Miceli, Emma Borrelli, Simonetta Fabrizi, Gianni G Savellini, Maria G Cusi

Abstract readObservational Study
In one paragraph

Observational study in Journal of medical virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gabriele AnichiniDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Chiara TerrosiDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Giulia AlessandriDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Giovanni B MiceliPreventive Medicine and Health Surveillance Unit, Santa Maria delle Scotte Hospital, Siena, Italy.
Emma BorrelliDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Simonetta FabriziPreventive Medicine and Health Surveillance Unit, Santa Maria delle Scotte Hospital, Siena, Italy.
Gianni G SavelliniDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Maria G CusiDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.ORCID 0000-0001-8869-8164

Funding

This work was supported by EU funding within the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT) (Maria G. Cusi).
6 · The paper itself

Abstract

Despite the availability of a highly efficacious vaccine, a global resurgence of measles infections has occurred, largely due to decreased vaccination coverage and waning immunity following the two-dose vaccination schedule. This study aims to assess the cellular immune response in individuals who did not respond to the two-dose MMR vaccine and evaluate the efficacy and durability of immune responses after booster doses. An observational study was conducted involving 24 individuals who were seronegative for measles years after completing the two-dose MMR vaccine schedule. Of these, 11 seroconverted after a single booster dose, while 13 required an additional booster. Antibody levels were monitored 1 and 3 years post-booster. Cellular immune responses were evaluated in 10 nonresponders by in vitro stimulation of PBMCs with UV-inactivated measles virus. In nonresponders, measles virus stimulation did not induce significant alterations in T, B, or NK cell populations, indicating a lack of measles-specific immune memory. However, stimulation with rubella induced a significant immune response. Booster doses in subjects with waning antibodies resulted in low IgG titers, which significantly declined over 3 years. Neutralizing antibody titers were also low for both double and single booster recipients. This study highlights the limited long-term efficacy of booster doses in individuals with waning immunity or nonresponsiveness to the measles vaccine. Current vaccination strategies relying on booster doses may not be sufficient for sustained protection in these individuals. Improving vaccine formulations to elicit stronger and longer-lasting immunity is essential for effective measles control and elimination.

Indexed as

Antibodies, NeutralizingAntibodies, ViralImmunization, SecondaryMeaslesMeasles-Mumps-Rubella VaccineAdolescentAdultChildChild, PreschoolFemaleHumansImmunity, CellularImmunization ScheduleImmunoglobulin GImmunologic MemoryMaleAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GMeasles-Mumps-Rubella Vaccineboosterimmune responsemeaslesMMRnonrespondersvaccine

Identifiers

PMID39722553
PMCPMC11669888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.